|Podcasts|September 6, 2018

Learning the Lung Cancer Landscape in Hanover

We traveled to Hanover, Maryland for a State of the Science SummitTM on Advanced Non–Small Cell Lung Cancer. The meeting covered the use of immunotherapy in metastatic and early-stage disease, management of immune-related toxicities, predictive biomarkers, and emerging therapies in small cell lung cancer.

We traveled to Hanover, Maryland for a State of the Science Summit^TM on Advanced Non—Small Cell Lung Cancer. The meeting covered the use of immunotherapy in metastatic and early-stage disease, management of immune-related toxicities, predictive biomarkers, and emerging therapies in small cell lung cancer.

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Learning the Lung Cancer Landscape in Hanover

Newsletter

Related Content

Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

How Community Oncology Experience Built the Foundation for a Dedicated Phase 1 Research Program: With D. Ross Camidge, MD, PhD; and Justin Call, MD

Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD

Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP

FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Addressing Unmet Needs in HER2+ Metastatic BTC

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies